A six-month implant for a swollen retina clears its Phase 2 test

For people whose diabetes has swollen the centre of the retina — a condition called diabetic macular edema that blurs reading and faces — treatment often means repeated injections. Eclipse Life Sciences says its biodegradable implant EC-104, designed to release medicine steadily for about six months, met its main safety goal in the BETTIS-1 Phase 2 trial and improved vision and retinal thickness more than the comparison implant at 24 weeks, in patients who had already responded poorly to standard therapy. The company now aims for Phase 3.

SDG 3 · Good health and well-being — Mechanism: tech innovation